Insider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Sells 36,372 Shares of Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Mark Ragosa sold 36,372 shares of the business’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $22.25, for a total value of $809,277.00. Following the sale, the chief financial officer now owns 22,958 shares of the company’s stock, valued at approximately $510,815.50. The trade was a 61.30 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Kiniksa Pharmaceuticals Trading Up 2.0 %

NASDAQ KNSA opened at $22.61 on Monday. The stock has a 50-day simple moving average of $19.99 and a 200 day simple moving average of $22.13. The company has a market capitalization of $1.64 billion, a PE ratio of -161.49 and a beta of 0.48. Kiniksa Pharmaceuticals, Ltd. has a 12 month low of $16.56 and a 12 month high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). The company had revenue of $122.50 million during the quarter, compared to the consensus estimate of $123.42 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company’s revenue for the quarter was up 46.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.35 EPS. As a group, sell-side analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quarry LP acquired a new position in Kiniksa Pharmaceuticals in the third quarter valued at about $50,000. Lazard Asset Management LLC acquired a new position in Kiniksa Pharmaceuticals in the fourth quarter valued at about $61,000. KLP Kapitalforvaltning AS acquired a new position in Kiniksa Pharmaceuticals in the fourth quarter valued at about $158,000. Bellevue Group AG acquired a new position in Kiniksa Pharmaceuticals in the fourth quarter valued at about $160,000. Finally, Tower Research Capital LLC TRC grew its stake in Kiniksa Pharmaceuticals by 117.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company’s stock valued at $168,000 after acquiring an additional 4,575 shares during the period. 53.95% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on KNSA shares. Wedbush restated an “outperform” rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research report on Tuesday, February 25th. Citigroup started coverage on Kiniksa Pharmaceuticals in a research report on Thursday. They set a “buy” rating and a $40.00 target price for the company. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $37.17.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.